Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Chee, L; Lee, N; Grigg, A; Chen, M; Schwarer, A; Szer, J; Ratnasingam, S; Raj, S; Lukito, P; Yeung, D; Hughes, T; Shanmuganathan, N

Author(s): Chee, L; Lee, N; Grigg, A; Chen, M; Schwarer, A; Szer, J; Ratnasingam, S; Raj, S; Lukito, P; Yeung, D; Hughes, T; Shanmuganathan, N;
Details: Publication Year 2024-07,Volume 54,Issue #7,Page 1214-1218
Journal Title: Internal Medicine Journal
Publication Type: Research article
Abstract: Asciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real-world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib-pretreated cohort.
Publisher: Wiley
Keywords: Humans; *Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Australia; Male; Middle Aged; *Protein Kinase Inhibitors/therapeutic use; Female; Treatment Outcome; Aged; Adult; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl/antagonists & inhibitors; Antineoplastic Agents/therapeutic use; Pyridazines/therapeutic use; Aged, 80 and over; Niacinamide/analogs & derivatives; Pyrazoles; asciminib; chronic myeloid leukaemia; tyrosine kinase inhibitor
Department(s): Clinical Haematology
Publisher's Version: https://doi.org/10.1111/imj.16446
Open Access at Publisher's Site: https://doi.org/10.1111/imj.16446
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-07-30 06:26:18

Last Modified: 2024-07-30 06:34:07